{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:07:49Z","timestamp":1761854869198,"version":"build-2065373602"},"reference-count":60,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.medcli.2019.01.017","type":"journal-article","created":{"date-parts":[[2019,3,8]],"date-time":"2019-03-08T08:37:12Z","timestamp":1552034232000},"page":"28-34","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["El trasplante alog\u00e9nico de progenitores hematopoy\u00e9ticos en la era de las nuevas terapias en la leucemia linfobl\u00e1stica aguda"],"prefix":"10.1016","volume":"153","author":[{"given":"Pere","family":"Barba","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Izaskun","family":"Elorza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2019.01.017_bib0305","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/blood-2007-10-116582","volume":"111","author":"Goldstone","year":"2008","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2019.01.017_bib0310","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1004383","article-title":"Reduced mortality after allogeneic hematopoietic-cell transplantation","volume":"363","author":"Gooley","year":"2010","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2019.01.017_bib0315","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.medcli.2017.03.027","article-title":"Acute lymphoblastic leukemia in adults: Steps ahead","volume":"149","author":"Ribera","year":"2017","journal-title":"Med Clin (Barc)."},{"key":"10.1016\/j.medcli.2019.01.017_bib0320","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1200\/JCO.2013.52.2425","volume":"32","author":"Ribera","year":"2014","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2019.01.017_bib0325","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3324\/haematol.2009.014274","volume":"95","author":"Oriol","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.medcli.2019.01.017_bib0330","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/bmt.2017.34","article-title":"Use of haploidentical stem cell transplantation continues to increase: The 2015 European Society for Blood and Marrow Transplant activity survey report","volume":"52","author":"Passweg","year":"2017","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.medcli.2019.01.017_bib0335","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1182\/blood-2008-07-168625","article-title":"Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: A prospective sibling donor versus no-donor comparison","volume":"113","author":"Cornelissen","year":"2009","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2019.01.017_bib0340","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1093\/annonc\/mds615","article-title":"NIH-defined graft-versus-host disease and evidence for a potent graft-versus-leukemia effect in patients with acute lymphoblastic leukemia","volume":"24","author":"Terwey","year":"2013","journal-title":"Ann Oncol."},{"key":"10.1016\/j.medcli.2019.01.017_bib0345","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/leu.2012.234","volume":"27","author":"Garand","year":"2013","journal-title":"Leukemia."},{"key":"10.1016\/j.medcli.2019.01.017_bib0350","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1182\/asheducation-2018.1.137","article-title":"Genetics and prognosis of ALL in children vs adults","volume":"2018","author":"Roberts","year":"2018","journal-title":"Hematology Am Soc Hematol Educ Program."},{"key":"10.1016\/j.medcli.2019.01.017_bib0355","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1038\/bcj.2014.48","article-title":"Different molecular levels of post-induction minimal residual disease may predict hematopoietic stem cell transplantation outcome in adult Philadelphia-negative acute lymphoblastic leukemia","volume":"4","author":"Bassan","year":"2014","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.medcli.2019.01.017_bib0360","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1182\/blood-2006-01-024729","article-title":"Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: A combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG)","volume":"109","author":"Schultz","year":"2007","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2019.01.017_bib0365","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1056\/NEJMoa1110169","article-title":"Outcomes after induction failure in childhood acute lymphoblastic leukemia","volume":"366","author":"Schrappe","year":"2012","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2019.01.017_bib0370","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-018-0094-0","article-title":"Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: A therapeutic advances in childhood leukemia & lymphoma study","author":"Sun","year":"2018","journal-title":"Leukemia."},{"key":"10.1016\/j.medcli.2019.01.017_bib0375","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1182\/blood-2010-03-273532","article-title":"Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)-rearranged acute lymphoblastic leukemia: results from the Interfant-99 Study","volume":"116","author":"Mann","year":"2010","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2019.01.017_bib0380","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.2014.58.9747","article-title":"Stem-cell transplantation in children with acute lymphoblastic leukemia: A prospective international multicenter trial comparing sibling donors with matched unrelated donors\u2014The ALL-SCT-BFM-2003 trial","volume":"33","author":"Peters","year":"2015","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2019.01.017_bib0385","doi-asserted-by":"crossref","first-page":"4961","DOI":"10.1182\/blood-2005-12-4942","volume":"107","author":"Eapen","year":"2006","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2019.01.017_bib0390","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.bbmt.2017.04.015","article-title":"Factors associated with long-term risk of relapse after unrelated cord blood transplantation in children with acute lymphoblastic leukemia in remission","volume":"23","author":"Page","year":"2017","journal-title":"Biol Blood Marrow Transplant."},{"key":"10.1016\/j.medcli.2019.01.017_bib0395","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.bbmt.2005.12.029","article-title":"A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission","volume":"12","author":"Marks","year":"2006","journal-title":"Biol Blood Marrow Transplant."},{"key":"10.1016\/j.medcli.2019.01.017_bib0400","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1038\/bmt.2015.202","volume":"50","author":"Kr\u00f6ger","year":"2015","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.medcli.2019.01.017_bib0405","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.bbmt.2017.11.025","article-title":"Intravenous busulfan compared with total body irradiation pretransplant conditioning for adults with acute lymphoblastic leukemia","volume":"24","author":"Kebriaei","year":"2018","journal-title":"Biol Blood Marrow Transplant."},{"key":"10.1016\/j.medcli.2019.01.017_bib0410","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.bbmt.2017.04.004","article-title":"Risk factors for subsequent central nervous system tumors in pediatric allogeneic hematopoietic cell transplant: A study from the center for international blood and marrow transplant research (CIBMTR)","volume":"23","author":"Gabriel","year":"2017","journal-title":"Biol Blood Marrow Transplant."},{"key":"10.1016\/j.medcli.2019.01.017_bib0415","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1016\/j.bbmt.2017.08.036","article-title":"Outcome analysis of pediatric patients with acute lymphoblastic leukemia treated with total body irradiation-free allogeneic hematopoietic stem cell transplantation: Comparison of patients with and without central nervous system involvement","volume":"23","author":"Hamidieh","year":"2017","journal-title":"Biol Blood Marrow Transplant."},{"key":"10.1016\/j.medcli.2019.01.017_bib0420","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1182\/blood-2010-02-266551","article-title":"Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: A retrospective study from the European Group for Blood and Marrow Transplantation","volume":"116","author":"Mohty","year":"2010","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2019.01.017_bib0425","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1182\/blood-2010-01-264077","article-title":"The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission","volume":"116","author":"Marks","year":"2010","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2019.01.017_bib0430","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.3109\/10428194.2015.1014365","article-title":"Impact of transplant eligibility and availability of a human leukocyte antigen-identical matched related donor on outcome of older patients with acute lymphoblastic leukemia","volume":"56","author":"Barba","year":"2015","journal-title":"Leuk Lymphoma."},{"key":"10.1016\/j.medcli.2019.01.017_bib0435","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.bbmt.2010.03.009","article-title":"Reduced-intensity conditioning regimens for allogeneic transplantation in children with acute lymphoblastic leukemia","volume":"16","author":"Verneris","year":"2010","journal-title":"Biol Blood Marrow Transplant."},{"key":"10.1016\/j.medcli.2019.01.017_bib0440","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2019.01.017_bib0445","doi-asserted-by":"crossref","first-page":"e387","DOI":"10.1016\/S2352-3026(17)30103-5","article-title":"Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: Results from the open-label, randomised, phase3 INO-VATE study","volume":"4","author":"Kantarjian","year":"2017","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.medcli.2019.01.017_bib0450","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(11)61938-7","article-title":"Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: An open-label, phase3, randomised controlled trial","volume":"379","author":"Corbacioglu","year":"2012","journal-title":"Lancet."},{"key":"10.1016\/j.medcli.2019.01.017_bib0455","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/bmt.2017.66","volume":"52","author":"Simonin","year":"2017","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.medcli.2019.01.017_bib0460","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3324\/haematol.2009.005694","article-title":"Cord blood transplantation: State of the art","volume":"94","author":"Gluckman","year":"2009","journal-title":"Haematologica."},{"key":"10.1016\/j.medcli.2019.01.017_bib0465","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1016\/S0140-6736(07)60915-5","article-title":"Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: A comparison study","volume":"369","author":"Eapen","year":"2007","journal-title":"Lancet."},{"key":"10.1016\/j.medcli.2019.01.017_bib0470","doi-asserted-by":"crossref","first-page":"378","DOI":"10.3324\/haematol.2013.091009","article-title":"Umbilical cord blood transplantation from unrelated donors in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"99","author":"Pi\u00f1ana","year":"2014","journal-title":"Haematologica."},{"key":"10.1016\/j.medcli.2019.01.017_bib0475","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1038\/s41409-018-0153-1","article-title":"Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report","volume":"53","author":"Passweg","year":"2018","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.medcli.2019.01.017_bib0480","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.bbmt.2016.11.008","article-title":"Haploidentical transplantation with post-transplantation cyclophosphamide for high-risk acute lymphoblastic leukemia","volume":"23","author":"Srour","year":"2017","journal-title":"Biol Blood Marrow Transplant."},{"key":"10.1016\/j.medcli.2019.01.017_bib0485","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1182\/blood-2014-09-599423","article-title":"\u03b3\u03b4 T-cell reconstitution after HLA-haploidentical hematopoietic transplantation depleted of TCR-\u03b1\u03b2+\/CD19+ lymphocytes","volume":"125","author":"Airoldi","year":"2015","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2019.01.017_bib0490","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/j.1365-2141.2012.09240.x","article-title":"Treatment of young patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia using increased dose of imatinib and deintensified chemotherapy before allogeneic stem cell transplantation","volume":"159","author":"Ribera","year":"2012","journal-title":"Br J Haematol."},{"key":"10.1016\/j.medcli.2019.01.017_bib0495","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1200\/JCO.2010.28.1287","article-title":"Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09\/00","volume":"28","author":"Bassan","year":"2010","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2019.01.017_bib0500","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/j.bbmt.2016.07.021","article-title":"Achieving molecular remission before allogeneic stem cell transplantation in adult patients with philadelphia chromosome-positive acute lymphoblastic leukemia: Impact on relapse and long-term outcome","volume":"22","author":"Lussana","year":"2016","journal-title":"Biol Blood Marrow Transplant."},{"key":"10.1016\/j.medcli.2019.01.017_bib0505","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/bmt.2015.217","article-title":"Impact of MRD and TKI on allogeneic hematopoietic cell transplantation for Ph+ ALL: A study from the adult ALL WG of the JSHCT","volume":"51","author":"Nishiwaki","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.medcli.2019.01.017_bib0510","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.bbmt.2012.08.021","article-title":"Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: A GRAALL study","volume":"19","author":"Tanguy-Schmidt","year":"2013","journal-title":"Biol Blood Marrow Transplant."},{"key":"10.1016\/j.medcli.2019.01.017_bib0515","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1200\/JCO.2016.69.3531","article-title":"Complete hematologic and molecular response in adult patients with relapsed\/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: Results from a phaseII, single-arm, multicenter study","volume":"35","author":"Martinelli","year":"2017","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2019.01.017_bib0520","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/bjh.12373","volume":"162","author":"Rives","year":"2013","journal-title":"Br J Haematol."},{"key":"10.1016\/j.medcli.2019.01.017_bib0525","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S1470-2045(12)70377-7","article-title":"Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): A randomised, open-label, intergroup study","volume":"13","author":"Biondi","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.medcli.2019.01.017_bib0530","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2019.01.017_bib0535","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S1470-2045(18)30011-1","article-title":"Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: A single-arm, phase2 study","volume":"19","author":"Kantarjian","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.medcli.2019.01.017_bib0540","first-page":"421723","article-title":"Impact of minimal residual disease, detected by flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia","volume":"2014","author":"Bar","year":"2014","journal-title":"Leuk Res Treatment."},{"key":"10.1016\/j.medcli.2019.01.017_bib0545","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.clml.2014.01.002","article-title":"The effect of peritransplant minimal residual disease in adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation","volume":"14","author":"Zhou","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.medcli.2019.01.017_bib0550","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1182\/blood-2014-09-599894","article-title":"Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia","volume":"125","author":"Dh\u00e9din","year":"2015","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2019.01.017_bib0555","doi-asserted-by":"crossref","first-page":"936","DOI":"10.3324\/haematol.2009.010843","article-title":"Relationship between minimal residual disease measured by multiparametric flow cytometry prior to allogeneic hematopoietic stem cell transplantation and outcome in children with acute lymphoblastic leukemia","volume":"95","author":"Elorza","year":"2010","journal-title":"Haematologica."},{"key":"10.1016\/j.medcli.2019.01.017_bib0560","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"13","author":"G\u00f6kbuget","year":"2018","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2019.01.017_bib0565","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2019.01.017_bib0570","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1200\/JCO.2014.58.4631","article-title":"Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending relapse: Results of the ALL-BFM-SCT 2003 trial","volume":"33","author":"Bader","year":"2015","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2019.01.017_bib0575","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1200\/JCO.2004.05.198","article-title":"Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: Possible role for pre-emptive immunotherapy?","volume":"22","author":"Bader","year":"2004","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2019.01.017_bib0580","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/bjh.14965","article-title":"Outcome of relapse after allogeneic HSCT in children with ALL enrolled in the ALL-SCT 2003\/2007 trial","volume":"180","author":"Kuhlen","year":"2018","journal-title":"Br J Haematol."},{"key":"10.1016\/j.medcli.2019.01.017_bib0585","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/j.bbmt.2018.03.002","article-title":"Second hematopoietic stem cell transplantation for post-transplantation relapsed acute leukemia in children: A retrospective EBMT-PDWP study","volume":"24","author":"Yaniv","year":"2018","journal-title":"Biol Blood Marrow Transplant."},{"key":"10.1016\/j.medcli.2019.01.017_bib0590","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2019.01.017_bib0595","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor Tcells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2019.01.017_bib0600","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S1470-2045(11)70386-2","article-title":"Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: A phase2 study","volume":"13","author":"Kantarjian","year":"2012","journal-title":"Lancet Oncol."}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775319300636?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775319300636?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T01:49:28Z","timestamp":1758419368000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775319300636"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S0025775319300636"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2019.01.017","relation":{},"ISSN":["0025-7753"],"issn-type":[{"type":"print","value":"0025-7753"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"El trasplante alog\u00e9nico de progenitores hematopoy\u00e9ticos en la era de las nuevas terapias en la leucemia linfobl\u00e1stica aguda","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2019.01.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}